| Similar Articles |
|---|
 |
The Motley Fool
June 7, 2007
Ryan Fuhrmann |
Big Gains for a Little Lab-Tester While bigger competitors stumble over each other, Bio-Reference keeps growing. This company may just be a welcome investment alternative as its two larger peers keep getting in each other's way.   |
The Motley Fool
June 6, 2007
Ryan Fuhrmann |
Foolish Forecast: Bio-Reference Labs Nudges Competitors The clinical laboratory testing company is set to release it second-quarter earnings report. Investors, here is what you can expect to see. |
The Motley Fool
September 6, 2007
Ryan Fuhrmann |
Bio-Reference Labs Passes the Test Small-cap lab-testing firm Bio-Reference Labs third-quarter results beat analysts projections by a decent margin, again proving it can compete with the big boys in the highly competitive New York metro area. |
The Motley Fool
April 20, 2007
Ryan Fuhrmann |
Diagnosing Quest Diagnostics Quest should recover from a recent, painful contract loss. Shares trade for a reasonable 17.5 times earnings, and even lower multiple of free cash flow. |
The Motley Fool
July 26, 2007
Ryan Fuhrmann |
LabCorp Leaps Forward LabCorp continues to fire on all cylinders. Investors, take note. |
The Motley Fool
July 25, 2007
Ryan Fuhrmann |
The Latest Procedure From Quest Diagnostics Quest Diagnostics took a hit earlier this year from the loss of a major contract, but the lab testing firm isn't down for the count. |
The Motley Fool
October 24, 2006
Ryan Fuhrmann |
LabCorp's Positive Results The good times continue. After taking a major client from Quest Diagnostics, the company reports strong third-quarter earnings. |
The Motley Fool
September 5, 2007
Ryan Fuhrmann |
Foolish Forecast: A Test From BioReference Labs In advance of lab-testing firm BioReference Labs Q3 earnings report, analysts are predicting another quarter of double-digit earnings for the small but fast-growing regional company. |
The Motley Fool
February 15, 2007
Ryan Fuhrmann |
LabCorp Takes Names Things are going well at LabCorp, but not so well at Quest Diagnostics. Still, the long-term attractiveness of the lab testing industry is favorable as the industry consolidates and demographics support increasing healthcare services. |
The Motley Fool
February 8, 2007
Rich Duprey |
Foolish Forecast: LabCorp Tests Positive The clinical lab-testing outfit is set to report its fourth-quarter 2006 earnings. Investors, here is what you can expect to see. |
The Motley Fool
September 7, 2005
Stephen D. Simpson |
The Little Lab That Could Bio-Reference is a small business with big potential. The company has an appealing cancer and genomics business (GenPath). For investors seeking successful yet unknown companies, this one is worth watching. |
The Motley Fool
March 9, 2007
Ryan Fuhrmann |
Referencing Bio-Reference's Q1: Fool by Numbers The Northeastern clinical lab test provider released first-quarter 2007 results. Income Statement Highlights... Margin Checkup... Balance Sheet Highlights... Cash Flow Highlights... |
The Motley Fool
April 19, 2007
Ryan Fuhrmann |
Quest Diagnostics Becomes Un-United: Fool by Numbers The lab-testing firm released first-quarter 2007 results: Income Statement Highlights... Margin Checkup... Balance Sheet Highlights... Cash Flow Highlights... |
The Motley Fool
April 27, 2007
Ryan Fuhrmann |
LabCorp Tests Positive LabCorp is doing well focusing on managed care -- so far. Recent results were "outstanding by every measure" and could signal even better things to come. Investors, take note. |
The Motley Fool
October 5, 2006
Rich Smith |
Great Chemistry at Lab Corp UnitedHealth Group has canceled its lab-testing contract with Quest and named Lab Corp. as its new service provider. This is an interesting situation for investors. |
The Motley Fool
February 4, 2011
Brian Orelli |
Glaxo Sold Quest Shares. Should You? Glaxo has somewhere else to spend the capital. Do you? |
The Motley Fool
June 11, 2007
Billy Fisher |
Big Dollars in Diagnostic Deals CIGNA extends multi-year deals to a pair of powerhouses. The Quest agreement is a comfort to investors, who now know that Quest will continue to be a contracted provider for one of the nation's largest health insurers. |
The Motley Fool
July 24, 2006
Ryan Fuhrmann |
The Quest for Market Share Quest Diagnostics' second-quarter earnings mostly meet expectations. What might the future hold for investors? |
Managed Care
April 2007
Scott Kober |
Managed Care Seeks More from Clinical Laboratories Contracting advantage has sometimes been with the nationwide labs, but health plans are getting serious about price, service, and patient data. |
The Motley Fool
July 21, 2005
W.D. Crotty |
The Lab Is Fab Laboratory Corporation of America produces more healthy results. Quest is a better value today based on earnings growth, but both companies are an excellent bet. |
The Motley Fool
December 16, 2010
Travis Hoium |
Bio-Reference Laboratories Shares Plunged: What You Need to Know Shares of laboratory service provider Bio-Reference Laboratories fell 10% briefly today after the company released earnings. |
The Motley Fool
June 15, 2005
Bobby Shethia |
A New Test for Quest The medical testing leader hopes to improve its steady performance via the rapidly growing gene-testing market. But sustained growth will require hefty capital expenditures. Investors, take note. |
The Motley Fool
March 31, 2011
David Williamson |
Embarking on a Profitable Quest Quest Diagnostics has been busy, snapping up a pair of smaller players and seeing its share price recover to near 52-week highs. Let's take a look at what these acquisitions mean going forward. |
The Motley Fool
February 13, 2009
Brian Orelli |
Lynch Would Love This Company Double-digit revenue growth in this market is nothing to sneeze at, but that's what LabCorp has delivered. |
The Motley Fool
February 17, 2005
Rich Smith |
LabCorp Tests Positive The results show strong bottom-line growth for the health-care test provider. Compared to the pricier Quest, it's at least a relative bargain price at which investors can own an interest in this essential piece of the health-care market. |
BusinessWeek
June 25, 2007
Gene G. Marcial |
Good Results At Bio-Reference Labs Specialty testing is delivering solid earnings for Bio-Reference Laboratories, the third-largest U.S. clinical test outfit. |
The Motley Fool
April 26, 2007
Ryan Fuhrmann |
LabCorp Measures Up: Fool by Numbers The lab testing firm released results for the first quarter 2007: Income Statement Highlights... Margin Checkup... Balance Sheet Highlights... Cash Flow Highlights... |
The Motley Fool
December 9, 2011
Paul Chi |
3 Europe-Proof Stocks for Your Portfolio These health-care stocks are Europe-proof. |
The Motley Fool
September 14, 2011
Frank Vinluan |
Here's How New Roche Cancer Drug Zelboraf Benefits LabCorp A new Roche cancer drug expected to become a blockbuster could also end up being a boon for laboratory and diagnostics firm LabCorp. |
The Motley Fool
April 16, 2008
Ryan Fuhrmann |
MEDTOX Fails the Test The Motley Fool - MEDTOX posted a weak quarter from a tough job market. |
The Motley Fool
April 20, 2005
Rich Smith |
LabCorp Hides Good News The company inexplicably hides its successful numbers from all but the most resourceful investors. |
The Motley Fool
December 15, 2008
Brian Orelli |
Medicine Gets a Little More Personal Genetic testing and personalized medicine are still in their infancy, but it's an emerging industry that should be huge in the long run. Which companies stand to benefit from it? |
Chemistry World
November 12, 2014
Phillip Broadwith |
Labcorp to buy Covance and enter contract research Medical diagnostics specialist Labcorp has agreed to buy contract research organization Covance for around $6 billion. |
